OCTAVE SPECIALTY GROUP INC
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
OSG$5.41+2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity (Unaudited)
| Three months ended September 30, 2026 and 2025 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders' Equity · Mezzanine | ||||||||||||||
| Octave Specialty Group, Inc. · Equity | ||||||||||||||
| (Dollars in thousands) · Total · PreferredStock · CommonStock · Additional Paid-inCapital · AccumulatedOtherComprehensiveIncome · RetainedEarnings · CommonStock Heldin Treasury,at Cost · Non-redeemableNCI (1) · Redeemable NCI (1) | ||||||||||||||
| Balance at June 30, 2026 | $817,845 | $— | $489 | $379,561 | $3,292 | $348,474 | $(33,063) | $119,092 | $197,529 | |||||
| Total net income (loss) | (12,221) | — | — | — | — | (13,797) | — | 1,576 | (637) | |||||
| Total other comprehensive income (loss) | (4,488) | — | — | — | (4,432) | — | — | (56) | (69) | |||||
| Stock-based compensation | 4,333 | — | — | 4,333 | — | — | — | — | — | |||||
| Cost of shares repurchased | — | — | — | — | — | — | — | — | — | |||||
| Cost of shares (acquired) issued under equity plan | (223) | — | — | — | — | (648) | 425 | — | — | |||||
| Changes to NCI | (937) | — | — | — | — | (244) | — | (693) | (2,307) | |||||
| Purchase of warrants | — | — | — | — | — | — | — | — | — | |||||
| Balance at September 30, 2026 | $804,309 | $— | $489 | $383,894 | $(1,140) | $333,785 | $(32,638) | $119,919 | $194,516 | |||||
| Balance at June 30, 2025 | $966,023 | $— | $489 | $347,939 | $(71,630) | $550,827 | $(30,124) | $168,522 | $252,685 | |||||
| Total net income (loss) | (111,457) | — | — | — | — | (112,620) | — | 1,163 | (271) | |||||
| Total other comprehensive income (loss) | 76,671 | — | — | — | 79,056 | — | — | (2,385) | (4,721) | |||||
| Stock-based compensation | 2,138 | — | — | 2,138 | — | — | — | — | — | |||||
| Cost of shares repurchased | — | — | — | — | — | — | — | — | ||||||
| Cost of shares (acquired) issued under equity plan | (197) | — | — | — | — | (2,626) | 2,429 | — | — | |||||
| Changes to NCI | (147) | — | — | — | — | 445 | — | (592) | (744) | |||||
| Purchase of Pivix | — | — | — | — | — | — | — | — | 1,359 | |||||
| Impact of sale of discontinued operations | (50,918) | — | — | — | — | — | — | (50,918) | — | |||||
| Issuance of warrants in connection with sale of AAC | 17,000 | — | — | 17,000 | — | — | — | — | — | |||||
| Balance at September 30, 2025 | $899,113 | $— | $489 | $367,077 | $7,426 | $436,026 | $(27,695) | $115,790 | $248,308 | |||||
| (1) NCI = Noncontrolling interest | ||||||||||||||
| Octave Specialty Group, Inc. | 5 | Third Quarter 2026 Form 10-Q |
|---|
| Nine months ended September 30, 2026 and 2025 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Stockholders' Equity · Mezzanine | |||||||||
| Octave Specialty Group, Inc. · Equity | |||||||||
| (Dollars in thousands) | Total | PreferredStock | CommonStock | Additional Paid-inCapital | AccumulatedOtherComprehensiveIncome | RetainedEarnings | CommonStock Heldin Treasury,at Cost | Non-redeemableNCI (1) | Redeemable NCI (1) |
| Balance at January 1, 2026 | $833,185 | $— | $489 | $369,860 | $8,483 | $370,431 | $(33,473) | $117,395 | $252,981 |
| Total net income (loss) | (29,305) | — | — | — | — | (35,077) | — | 5,772 | 1,428 |
| Total other comprehensive income (loss) | (11,575) | — | — | — | (9,623) | — | — | (1,952) | (3,891) |
| Stock-based compensation | 13,208 | — | — | 13,208 | — | — | — | — | — |
| Cost of shares repurchased | — | — | — | — | — | — | — | — | — |
| Cost of shares (acquired) issued under equity plan | (560) | — | — | — | — | (1,395) | 835 | — | — |
| Changes to NCI | 4,211 | — | — | 5,681 | — | (174) | — | (1,296) | (56,002) |
| Purchase of warrants | (4,855) | — | — | (4,855) | — | — | — | — | |
| Balance at September 30, 2026 | $804,309 | $— | $489 | $383,894 | $(1,140) | $333,785 | $(32,638) | $119,919 | $194,516 |
| Balance at January 1, 2025 | $996,119 | $— | $489 | $331,007 | $(188,436) | $683,643 | $(28,339) | $197,755 | $199,402 |
| Total net income (loss) | (228,406) | — | — | — | — | (231,710) | — | 3,304 | (1,012) |
| Total other comprehensive income (loss) | 205,533 | — | — | — | 195,862 | — | — | 9,671 | 14,667 |
| Stock-based compensation | 6,924 | — | — | 6,924 | — | — | — | — | — |
| Cost of shares repurchased | (3,301) | — | — | — | — | — | (3,301) | — | — |
| Cost of shares (acquired) issued under equity plan | (1,805) | — | — | — | — | (5,750) | 3,945 | — | — |
| Changes to NCI | (42,033) | — | — | 12,146 | — | (10,157) | — | (44,022) | 33,892 |
| Purchase of Pivix | — | — | — | — | — | — | — | — | 1,359 |
| Impact of sale of discontinued operations | (50,918) | — | — | — | — | — | — | (50,918) | — |
| Issuance of warrants in connection with sale of AAC | 17,000 | — | — | 17,000 | — | — | — | — | — |
| Balance at September 30, 2025 | $899,113 | $— | $489 | $367,077 | $7,426 | $436,026 | $(27,695) | $115,790 | $248,308 |
| Octave Specialty Group, Inc. | 6 | Third Quarter 2026 Form 10-Q |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.